Kindeva's Leadership Transition to Propel Growth
Kindeva, a prominent global contract development and manufacturing organization (CDMO), has recently made key leadership changes aimed at driving strategic growth in its core business sectors. Focused on innovations in parenteral and inhaled drug delivery, Kindeva's leadership transition signifies a transformative approach towards enhancing the company's growth trajectory.
New Leadership Announcement
As of January 1, 2026, David Stevens has been appointed as the new Chief Executive Officer of Kindeva. Previously serving as the President of the company, David brings a wealth of experience in managing successful teams through periods of significant growth and operational expansion. His innovative mindset and dedication to improving patient outcomes align perfectly with Kindeva's mission.
Milton Boyer's Continued Influence
Milton Boyer, who served as the former Chief Executive Officer, is transitioning to a role as an independent member of the Board of Directors. In this capacity, he will continue to play an important role in providing strategic guidance to the company while ensuring a seamless shift in leadership.
Vision for the Future
In his statement regarding his new role, David Stevens expressed his honor in succeeding Milton and his commitment to advancing Kindeva's legacy of innovation and industry leadership. He highlighted the company's deep-rooted capabilities and the expertise of its dedicated employees as vital components of its bright future. Kindeva aims to deliver exceptional drug delivery solutions while ensuring high standards of service and reliability to its customers.
Support from Altaris Leadership
George Aitken-Davies, Co-founder and Managing Director at Altaris, also shared his support for the new leadership. He noted the significant progress Kindeva has made in establishing a solid foundation for future growth and expressed confidence in David's ability to lead the company toward executing its strategic objectives effectively.
Commitment to Strategic Growth
This leadership transition is part of a broader succession plan that began in October 2025. Kindeva is dedicated to ensuring stability and continuity amid these changes, reinforcing its commitment to achieving long-term success in the healthcare sector.
About Kindeva
Kindeva is proud to be at the forefront of drug delivery innovation, as it champions its mission to "Manufacture More Tomorrows™" for patients all over the globe. With its world-class facilities and extensive CDMO services, Kindeva goes beyond mere manufacturing, providing strategic value to its partners. The company's global network comprises ten manufacturing and R&D sites equipped with state-of-the-art technology for aseptic fill-finish operations, as well as advanced sustainable inhalation propellant technology.
Offering Comprehensive Solutions
At Kindeva, the expertise spans injectable, pulmonary, nasal, and dermal drug delivery methods, allowing the company to meet current demands and explore future possibilities in medication delivery. This dedication to innovation enhances Kindeva's role as a key player in the healthcare landscape.
About Altaris
Since its founding in 2003, Altaris has focused exclusively on investing in healthcare companies, aiming to create value for the healthcare system and providing attractive returns for its investors. Altaris' robust portfolio includes numerous investments across various healthcare subsectors, illustrating its commitment to growth and success.
Frequently Asked Questions
What recent leadership changes have occurred at Kindeva?
Kindeva has appointed David Stevens as the new CEO, replacing Milton Boyer, who now serves on the Board of Directors.
What is Kindeva's primary business focus?
Kindeva specializes in contract development and manufacturing, primarily in parenteral and inhaled drug delivery solutions.
What is Kindeva's mission?
Kindeva's mission is to "Manufacture More Tomorrows™" for patients, driving innovation in drug delivery systems.
How does Kindeva ensure stability during transitions?
The company has initiated a carefully planned succession strategy, affirming its commitment to stability and long-term success.
What role does Altaris play in Kindeva's operations?
Altaris is an investment firm that provides strategic guidance and support to Kindeva, emphasizing growth and value creation in the healthcare sector.
